<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>New compound</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Peptide GFRAL/RET antagonists against GDF15-induced effects of chemotherapy</title>
      <description>
        <![CDATA[Syracuse University recently presented a comprehensive preclinical program describing the rational design and optimization of peptide antagonists targeting the GDF15/GFRAL/RET receptor complex to mitigate nausea, emesis, anorexia and wasting associated with chemotherapy-induced stress signaling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730453</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730453-peptide-gfral-ret-antagonists-against-gdf15-induced-effects-of-chemotherapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecule-dropper-tubes-abstract-science.webp?t=1731606498" type="image/jpeg" medium="image" fileSize="206914">
        <media:title type="plain">Art concept for drug research</media:title>
      </media:content>
    </item>
    <item>
      <title>Targeted MLKL degradation drives parthanatos in HCC</title>
      <description>
        <![CDATA[Mixed lineage kinase domain-like pseudokinase (MLKL), a key effector of necroptosis, is highly expressed in hepatocellular carcinoma (HCC), and its targeting may promote parthanatos-mediated immunogenic cell death. Researchers from the Chinese Academy of Sciences and collaborators described the discovery and preclinical characterization of C-116, a MLKL PROTAC degrader developed using AI-assisted rational drug discovery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730450</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730450-targeted-mlkl-degradation-drives-parthanatos-in-hcc</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-blood-vessels.webp?t=1682600393" type="image/jpeg" medium="image" fileSize="250834">
        <media:title type="plain">3D representation of tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Cisplatin prodrug enables safe PD-L1 targeted chemo-immunotherapy</title>
      <description>
        <![CDATA[Cisplatin is widely used in chemotherapy regimens for many solid tumors, yet its therapeutic benefit is counterbalanced by significant toxicity and immunologically related limitations. Researchers from Jiangxi University of Chinese Medicine described the preclinical efficacy of the PD-L1-targeted cisplatin prodrug MN42-81, designed to overcome these limitations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730449</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730449-cisplatin-prodrug-enables-safe-pd-l1-targeted-chemo-immunotherapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Immuno-oncology-checkpoint-inhibitors-PD1-PDL1.webp?t=1716910733" type="image/jpeg" medium="image" fileSize="297091">
        <media:title type="plain">Illustration of interaction between PD-1 and PD-L1 blocked by therapeutic antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Selective STAT3 degrader with efficacy in hematological cancer models</title>
      <description>
        <![CDATA[Signal transducer and activator of transcription 3 (STAT3) is a central mediator of cytokine and growth factor signaling and is aberrantly activated in approximately 70% of human cancers. Persistent STAT3 signaling drives tumor proliferation, survival, metastasis, angiogenesis, immune evasion and inflammation. Researchers from the University of Michigan reported the discovery and preclinical characterization of SD-965, a selective STAT3 PROTAC degrader.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730448</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730448-selective-stat3-degrader-with-efficacy-in-hematological-cancer-models</link>
    </item>
    <item>
      <title>MASTL inhibitor shows robust antitumor efficacy</title>
      <description>
        <![CDATA[Microtubule-associated serine/threonine kinase-like protein (MASTL) is a key regulator of mitotic progression and cell-cycle control. Researchers from the Korea Institute of Radiological and Medical Sciences reported the preclinical efficacy of MKI-3, a selective MASTL inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730375</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730375-mastl-inhibitor-shows-robust-antitumor-efficacy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-gene-therapy-T-cell.webp?t=1588880268" type="image/png" medium="image" fileSize="561911">
        <media:title type="plain">Cancer cell, dropper, test tubes</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel caspase-2 inhibitor shows in vivo neuroprotective effects</title>
      <description>
        <![CDATA[Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This fragment accumulates at synapses, disrupts glutamatergic signaling and contributes to cognitive impairment in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730346</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730346-novel-caspase-2-inhibitor-shows-in-vivo-neuroprotective-effects</link>
    </item>
    <item>
      <title>Selective RXRγ degrader shows efficacy in prostate cancer models</title>
      <description>
        <![CDATA[Retinoid X receptor γ (RXRγ) is a key nuclear receptor that sustains androgen receptor (AR) signaling. In castration-resistant prostate cancer (CRPC), RXRγ contributes to disease progression by maintaining adaptive transcriptional networks that promote therapy resistance and tumor cell survival.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730328</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730328-selective-rxr-degrader-shows-efficacy-in-prostate-cancer-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-prostate-biopsy.webp?t=1682520193" type="image/png" medium="image" fileSize="1960847">
        <media:title type="plain">Photomicrograph of core biopsy of prostate gland showing histology of adenocarcinoma in patient with elevated PSA.</media:title>
      </media:content>
    </item>
    <item>
      <title>CHNQD-01522 microtubule destabilizer demonstrates efficacy in HCC models</title>
      <description>
        <![CDATA[Researchers from Syngenta AG and collaborators reported the preclinical characterization of CHNQD-01522, a microtubule-targeting agent designed based on the marine natural product penipanoid C, in hepatocellular carcinoma (HCC) models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730191</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730191-chnqd-01522-microtubule-destabilizer-demonstrates-efficacy-in-hcc-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/microtubule-structure-scientific-3D-render.webp?t=1775662264" type="image/jpeg" medium="image" fileSize="405330">
        <media:title type="plain">3D rendering of microtubule: Minus-end, GDP-lattice and GTP-cap at plus-end</media:title>
        <media:description type="plain">Scientific structure of microtubule.</media:description>
      </media:content>
    </item>
    <item>
      <title>New LRH-1 antagonists exhibit antitumor activity in prostate cancer models</title>
      <description>
        <![CDATA[Liver receptor homolog-1 (LRH-1) is a nuclear receptor that promotes the transcription of genes encoding key steroidogenic enzymes, thereby facilitating de novo androgen biosynthesis within the prostate tumor microenvironment. Researchers from Qilu Pharmaceutical Co. Ltd. reported the discovery and preclinical characterization of a series of novel LRH-1 antagonists.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730171</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730171-new-lrh-1-antagonists-exhibit-antitumor-activity-in-prostate-cancer-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Prostate-cancer.webp?t=1674835049" type="image/png" medium="image" fileSize="839914">
        <media:title type="plain">3D illustration showing tumor inside prostate gland and closeup view of cancer cells</media:title>
      </media:content>
    </item>
    <item>
      <title>BRD9 PROTAC shows efficacy in sarcoma and leukemia models</title>
      <description>
        <![CDATA[In both acute myeloid leukemia (AML) and synovial sarcoma (SS), targeting BRD9 disrupts oncogenic transcriptional programs, including MYC, leading to reduced proliferation and induction of apoptosis. Researchers from Pamplona Therapeutics (Shenzhen) Co. Ltd. reported the discovery and preclinical efficacy profile of XYD-270, a BRD9-targeting PROTAC, in models of SS and AML.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730016</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730016-brd9-protac-shows-efficacy-in-sarcoma-and-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/leukemia-lymphoma-blood-cancer.webp?t=1724424490" type="image/jpeg" medium="image" fileSize="506006">
        <media:title type="plain">Art concept for hematologic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Selective PARP1 inhibitor disclosed</title>
      <description>
        <![CDATA[Researchers from the Chinese Academy of Sciences reported the design and preclinical characterization of YCH-3971, a selective PARP1 inhibitor developed for the treatment of BRCA-mutated tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729935</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729935-selective-parp1-inhibitor-disclosed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-target-destroy.webp?t=1731081970" type="image/jpeg" medium="image" fileSize="520172">
        <media:title type="plain">Illustration of cancer cell in crosshairs being destroyed</media:title>
      </media:content>
    </item>
    <item>
      <title>MMV-1581361 combines strong antimalarial efficacy with transmission blockade</title>
      <description>
        <![CDATA[Researchers from GSK plc and collaborators described the identification of MMV-1581361, a <em>Pf</em>ATP4 inhibitor, and its efficacy in models of malaria. The compound originates from MMV-020136, following structure-activity relationship studies to optimize antimalarial activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729934</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729934-mmv-1581361-combines-strong-antimalarial-efficacy-with-transmission-blockade</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Malaria-red-blood-cell-parasite-release.webp?t=1693493889" type="image/jpeg" medium="image" fileSize="298167">
        <media:title type="plain">Release of malaria parasites from red blood cell</media:title>
      </media:content>
    </item>
    <item>
      <title>HX-16108 holds promise for treating inflammatory skin diseases</title>
      <description>
        <![CDATA[Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has developed a bispecific antibody targeting both IL-13 and IL-31, HX-16108, with an extended half-life.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729592</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-atopic-dermatitis2.webp?t=1588881560" type="image/png" medium="image" fileSize="357317">
        <media:title type="plain">Skin irritation on hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Dual degrader shows activity in acute myeloid leukemia models</title>
      <description>
        <![CDATA[Researchers in China reported the discovery and preclinical characterization of ZX-079, a novel BRD4/CBP PROTAC degrader.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729325</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729325-dual-degrader-shows-activity-in-acute-myeloid-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/AML-cells-acute-myeloid-leukemia.webp?t=1663340307" type="image/png" medium="image" fileSize="1258935">
        <media:title type="plain">Microscopic image of acute myeloid leukemia (AML) cells.</media:title>
        <media:description type="plain">Acute myeloid leukemia cells. Credit: Cincinnati Children's
</media:description>
      </media:content>
    </item>
    <item>
      <title>Newly described selective CDK6 degrader exhibits potential in leukemia models</title>
      <description>
        <![CDATA[Researchers from Specally (Wuhan) Life Technology Co. Ltd. have disclosed the discovery and preclinical profile of WWZ-11-098, a non-palbociclib-based, selective cyclin-dependent kinase 6 (CDK6) degrader in models of leukemia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729154</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729154-newly-described-selective-cdk6-degrader-exhibits-potential-in-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Leukemia.webp?t=1588713330" type="image/png" medium="image" fileSize="421137">
        <media:title type="plain">Leukemia illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>First-in-class non-β-lactam targeting AMR gram-negative pathogens</title>
      <description>
        <![CDATA[Antimicrobial resistance (AMR) is increasingly compromising the effectiveness of essential antibiotics, resulting in higher global mortality and morbidity rates. Despite this urgent need, few new antibiotics, particularly against gram-negative bacteria, are in development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728921</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728921-first-in-class-non-lactam-targeting-amr-gram-negative-pathogens</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Klebsiella-pneumoniae-colonies-petri-dish.webp?t=1739551421" type="image/jpeg" medium="image" fileSize="151083">
        <media:title type="plain">Klebsiella pneumoniae colonies in petri dish</media:title>
      </media:content>
    </item>
    <item>
      <title>New compound against tumors with aberrant FGFR2 signaling</title>
      <description>
        <![CDATA[Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase that regulates signaling pathways controlling cell survival and proliferation. Dysregulation of FGFR2, through amplification or activating mutations, contributes to tumor development, making it an attractive target for therapeutic intervention in oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728919</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728919-new-compound-against-tumors-with-aberrant-fgfr2-signaling</link>
    </item>
    <item>
      <title>CZL-077 shows robust preclinical antitumor activity</title>
      <description>
        <![CDATA[Researchers from Fudan University reported the development of CZL-077, a p300/CBP bromodomain inhibitor. p300 and CREB-binding protein (CBP) are closely related histone acetyltransferases that play central roles in regulating gene expression. Dysregulation of these proteins has been implicated in tumorigenesis and the development of therapy resistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728887</guid>
      <pubDate>Mon, 16 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728887-czl-077-shows-robust-preclinical-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vials-syringes-and-pills.webp?t=1760736677" type="image/jpeg" medium="image" fileSize="674125">
        <media:title type="plain">Vials, syringes, and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>New CDK12/13 dual degrader for TNBC</title>
      <description>
        <![CDATA[Triple-negative breast cancer (TNBC) cells depend on the transcriptional kinases CDK12 and CDK13 to maintain DNA damage response gene expression and manage replication stress. Due to their functional overlap, inhibition of a single kinase may permit compensatory activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728815</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728815-new-cdk12-13-dual-degrader-for-tnbc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-tumor.webp?t=1755066074" type="image/jpeg" medium="image" fileSize="171386">
        <media:title type="plain">Illustration of tumor in breast</media:title>
      </media:content>
    </item>
    <item>
      <title>SY-589 suppresses HR-deficient tumors via POLθ inhibition</title>
      <description>
        <![CDATA[DNA polymerase θ (POLθ) is a specialized, error-prone DNA polymerase that promotes the repair of DNA double-strand breaks through theta-mediated end joining (TMEJ), an alternative pathway that operates independently of homologous recombination.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728630</guid>
      <pubDate>Thu, 05 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728630-sy-589-suppresses-hr-deficient-tumors-via-pol-inhibition</link>
    </item>
    <item>
      <title>Thiazole derivatives show drug-like properties as broad-spectrum antirhinovirus agents</title>
      <description>
        <![CDATA[Challenges in developing antiviral agents against rhinoviruses (RVs) include their genetic heterogeneity (over 160 serotypes), rapid evolution of the viral capsid and serotype-specific immunity. To overcome these limitations, alternative approaches targeting host cellular pathways essential for viral replication have been proposed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728455</guid>
      <pubDate>Mon, 02 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728455-thiazole-derivatives-show-drug-like-properties-as-broad-spectrum-antirhinovirus-agents</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Rhinovirus-common-cold.webp?t=1770047650" type="image/jpeg" medium="image" fileSize="535007">
        <media:title type="plain">Illustration of rhinovirus particles</media:title>
      </media:content>
    </item>
    <item>
      <title>Centessa’s CNT-9982 shows promise for MDD</title>
      <description>
        <![CDATA[Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy and idiopathic hypersomnia. Based on recent findings, it has been hypothesized that they may also regulate cognition, mood and other neuropsychiatric functions. Furthermore, dysregulated orexin signaling has been reported in patients with major depressive disorder (MDD) with suicide attempts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728187</guid>
      <pubDate>Wed, 21 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728187-centessas-cnt-9982-shows-promise-for-mdd</link>
    </item>
    <item>
      <title>Orum’s ORM-1153 outperforms venetoclax in AML</title>
      <description>
        <![CDATA[Acute myeloid leukemia (AML) is a hematological cancer with limited treatment options and characterized by frequent relapse and poor prognosis. The only approved antibody-drug conjugate for AML is gemtuzumab ozogamicin, which targets CD33.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727444</guid>
      <pubDate>Wed, 24 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727444-orums-orm-1153-outperforms-venetoclax-in-aml</link>
    </item>
    <item>
      <title>A PROTAC degrader of RIPK1 with better drug properties</title>
      <description>
        <![CDATA[Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize tumors to immunotherapy against PD-1. Degrading the entire protein seems to be essential: merely blocking its kinase activity does not sensitize tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726850</guid>
      <pubDate>Fri, 05 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726850-a-protac-degrader-of-ripk1-with-better-drug-properties</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecular-science-research-art-3.webp?t=1726673896" type="image/jpeg" medium="image" fileSize="184043">
        <media:title type="plain">Molecular research art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>PARP-ATR dual inhibitor shows preclinical activity against TNBC</title>
      <description>
        <![CDATA[Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have shown improved therapeutic response to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi).]]>
      </description>
      <guid>http://www.bioworld.com/articles/726700</guid>
      <pubDate>Tue, 02 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726700-parp-atr-dual-inhibitor-shows-preclinical-activity-against-tnbc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Science-researcher-structures-atoms-micoroscope.webp?t=1692196171" type="image/jpeg" medium="image" fileSize="140664">
        <media:title type="plain">Scientist looking in microscope, chemical structure concept image</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel PROTAC based on GDC-0810 against ER-positive breast cancer</title>
      <description>
        <![CDATA[In an effort to develop more effective estrogen receptor α (ERα) inhibitors, researchers at Nanjing University of Chinese Medicine and collaborators aimed to develop a proteolysis targeting chimera (PROTAC) against the receptor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726588</guid>
      <pubDate>Thu, 27 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726588-novel-protac-based-on-gdc-0810-against-er-positive-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Dec-2020/Science-breast-cancer-cell-12-9.webp?t=1607542510" type="image/png" medium="image" fileSize="570840">
        <media:title type="plain">Breast cancer cell</media:title>
        <media:description type="plain">Breast cancer cell. Credit: Bruce Wetzel and Harry Schaefer, NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>New FGFR3 inhibitors offer best-in-class selectivity, potency</title>
      <description>
        <![CDATA[FGFR3 genomic alterations, including S249C as the most common, are recognized oncogenic drivers in 10%-60% of bladder cancers depending on the disease stage. Onco3r Therapeutics BV recently reported the identification of a novel series of highly potent, isoform-selective small-molecule FGFR3 inhibitors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726572</guid>
      <pubDate>Wed, 26 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726572-new-fgfr3-inhibitors-offer-best-in-class-selectivity-potency</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Bladder-illustration.webp?t=1615559821" type="image/png" medium="image" fileSize="432209">
        <media:title type="plain">Bladder </media:title>
      </media:content>
    </item>
    <item>
      <title>Selective CDK2 inhibitor is active in multiple solid tumor models</title>
      <description>
        <![CDATA[Researchers from Eilean Therapeutics LLC and collaborators presented the discovery and characterization of a new, selective CDK2 inhibitor showing potent in vitro and in vivo activity at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726528</guid>
      <pubDate>Mon, 24 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726528-selective-cdk2-inhibitor-is-active-in-multiple-solid-tumor-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Targeted-cancer-cell.webp?t=1741213881" type="image/jpeg" medium="image" fileSize="269059">
        <media:title type="plain">Targeted cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Small-molecule SMARCA2 inhibitors to treat SMARCA4-mutant cancers</title>
      <description>
        <![CDATA[At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Onco3r Therapeutics BV presented a novel series of selective SMARCA2 small-molecule inhibitors with a best-in-class potency and selectivity profile.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726526</guid>
      <pubDate>Mon, 24 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726526-small-molecule-smarca2-inhibitors-to-treat-smarca4-mutant-cancers</link>
    </item>
    <item>
      <title>Novel B7-H7-targeted ADC NPX-125 active in solid tumors</title>
      <description>
        <![CDATA[Nextpoint Therapeutics Inc. presented their novel B7-H7-directed antibody-drug conjugate (ADC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/726413</guid>
      <pubDate>Fri, 21 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726413-novel-b7-h7-targeted-adc-npx-125-active-in-solid-tumors</link>
    </item>
  </channel>
</rss>
